Contribution of abdominal obesity and hypertriglyceridemia to impaired fasting glucose and coronary artery disease

St‐Pierre, Julie; Lemieux, Isabelle; Vohl, Marie‐Claude; Perron, Patrice; Tremblay, G; Després, Jean‐Pierre; Gaudet, Daniel

doi:10.1016/s0002-9149(02)02378-0

Cited by 119 publications

(82 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…14,15 These authors showed that men with HTGW were at increased risk for coronary artery disease (CAD) and suggested that the HTGW phenotype could represent a simple and inexpensive tool to screen for high-risk subjects. 14,16 Similar findings were reported in a few other cross-sectional studies. 17,18 Evidence of the relationship between HTGW with CVD risk in prospective studies is scarce.…”

Section: Introductionsupporting

confidence: 87%

“…In another study by the same authors, the cross-sectional relationships of the HTGW phenotype with CAD were analyzed according to fasting glucose level. 16 The OR for the HTGW group, as compared to low WC/low TG group, was 8.5 (3.5-20.4) in subjects with raised fasting glucose (6.1-6.9 mmol/l) and 5.4 (3.1-9.3) in those with normal glucose level (o6.1 mmol/l). 16 Other risk factors were, however, not taken into account.…”

Section: Discussionmentioning

confidence: 90%

“…16 The OR for the HTGW group, as compared to low WC/low TG group, was 8.5 (3.5-20.4) in subjects with raised fasting glucose (6.1-6.9 mmol/l) and 5.4 (3.1-9.3) in those with normal glucose level (o6.1 mmol/l). 16 Other risk factors were, however, not taken into account. In a crosssectional analysis in Turkish men, HTGW was also predictive of age-adjusted fatal and non-fatal CAD risk.…”

Section: Discussionmentioning

confidence: 90%

“…16,18,25 In a seminal study by Lemieux et al 14 (n ¼ 287 men), HTGW was predictive of angiographically assessed CAD with an odds ratio (OR) of 3.6 (1.2-10.9) compared to the low WC/ low TG group as reference. In another study by the same authors, the cross-sectional relationships of the HTGW phenotype with CAD were analyzed according to fasting glucose level.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Hypertriglyceridemic waist and 7.5-year prospective risk of cardiovascular disease in asymptomatic middle-aged men

et al. 2006

View full text Add to dashboard Cite

Background: Few studies suggest that the combined increase in plasma triglycerides (TG) and in waist circumference (WC), termed 'hypertriglyceridemic waist' (HTGW), is an interesting marker of risk for cardiovascular disease (CVD). Objective: Using cutoffs used for defining HTGW, we examined the prospective association of HTGW with CVD risk in a French cohort of men. Design: Men were participants in the SU.VI.MAX study, an intervention trial testing the impact of an antioxidant supplementation on chronic diseases. Data were collected in 1994-1996 in 3430 men followed up for 7.5 years. Cutoffs used for defining HTGW were WC X90 cm and TG X2 mmol/l. We assessed the relative risk (RR) (95% confidence interval (CI)) of CVD in groups defined according to both WC and TG levels. Results: In this population, 41.2% of the subjects were classified as low WC/low TG, 43.2% as high WC/low TG, 3.5% as low WC/high TG and 12.1% as HTGW. During follow-up, 122 subjects had a CVD event. In this group, HTGW prevalence was 26.2%. After adjustment for age, RR (95% CI) for CVD for the HTGW group showed the highest association with CVD risk: 2.13 (1.21-3.76), using low WC/ low TG as the reference group. Conclusion: HTGW was associated with the risk of CVD after 7.5 years of follow-up in a low-risk middle-aged men population. This marker may be used as a useful clinical tool to screen for men at risk of CVD.

show abstract

Section: Introductionsupporting

confidence: 87%

Section: Discussionmentioning

confidence: 90%

Section: Discussionmentioning

confidence: 90%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Hypertriglyceridemic waist and 7.5-year prospective risk of cardiovascular disease in asymptomatic middle-aged men

et al. 2006

View full text Add to dashboard Cite

show abstract

“…20 Among these screening tools, there is compelling data suggesting that the presence of an elevated waist circumference combined with hypertriglyceridemia is sufficient to identify a large proportion of patients meeting the NCEP-ATP III criteria for the metabolic syndrome. [21][22][23][24][25][26][27][28][29][30][31] The dyslipidemia of abdominal obesity: beyond LDL-cholesterol…”

mentioning

confidence: 99%

Contribution of CB1 blockade to the management of high-risk abdominal obesity

Lemieux

Alméras³

2006

Int J Obes

View full text Add to dashboard Cite

The worldwide increase in the prevalence of type 2 diabetes represents a tremendous challenge for our healthcare system, especially if we consider that this phenomenon is largely explained by the epidemic of obesity. However, despite the wellrecognized increased morbidity and mortality associated with an elevated body weight, there is now more and more evidence highlighting that abdominal adipose tissue is the fat depot that conveys the greatest risk of metabolic complications. This cluster of metabolic abnormalities has been referred to as the metabolic syndrome and this condition is largely the consequence of abdominal obesity, especially when accompanied by a high accumulation of visceral adipose tissue. This cluster of metabolic complications has also been found to be predictive of a substantially increased risk of coronary heart disease beyond the presence of traditional risk factors. Moreover, a moderate weight loss in initially abdominally obese patients is associated with a selective mobilization of visceral adipose tissue, leading to improvements in the metabolic risk profile predictive of a reduced risk of coronary heart disease and of type 2 diabetes. The recent discovery of the endocannabinoid-CB 1 receptor system and of its impact on the regulation of energy metabolism represents a significant advance, which will help physicians target abdominal obesity and its related metabolic complications. In this regard, studies have shown that rimonabant therapy (the first developed CB 1 blocker) could be useful for the management of clustering cardiovascular disease risk factors in high-risk abdominally obese patients through its effects not only on energy balance but also on adipose tissue metabolism. For instance, the presence of CB 1 receptors in adipose tissue and the recently reported effect of rimonabant on adiponectin production by adipose cells may represent a key factor responsible for the weight loss-independent effect of this CB 1 blocker on cardiometabolic risk variables.

show abstract

Atherosclerosis: Risk Factors and Medical Management

DePalma¹,

Hayes²

2005

Vascular Surgery

View full text Add to dashboard Cite

Contribution of abdominal obesity and hypertriglyceridemia to impaired fasting glucose and coronary artery disease

Cited by 119 publications

References 15 publications

Hypertriglyceridemic waist and 7.5-year prospective risk of cardiovascular disease in asymptomatic middle-aged men

Hypertriglyceridemic waist and 7.5-year prospective risk of cardiovascular disease in asymptomatic middle-aged men

Contribution of CB1 blockade to the management of high-risk abdominal obesity

Atherosclerosis: Risk Factors and Medical Management

Contact Info

Product

Resources

About